Glycotest

United States
Troy, New Hampshire, United States, 10005

Company profile

Glycotest company profile

Glycotest Diagnostics is developing unique and non-invasive blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis. Our technology could revolutionize care and treatment for groups at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease. Over 25 million people in the US, 800 million worldwide, and another 1.2 billion in jeopardy due to fatty liver disease may benefit from Glycotest’s products.

Business identity

Contact email
[email protected]
Phone number
+1 484 431 3483
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Postal code
10005
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$10M
Last funding
Series A / $10M / 2018-10-23
Last equity funding
Series A / $10M
Investors
1
Lead investors
1
Founders
1
Articles
5

Founders and investors

Founders

Timothy Block

Lead investors

Fosun Pharma

Investors

Fosun Pharma